

Referral for Outpatient Remdesivir for COVID-19



Last Updated: February 2, 2024

EMAIL COMPLETED FORM TO: COVIDCare@uhn.ca or fax 416-340-4135

Referral form may not be processed if all sections are not completed.

IMPORTANT: In order to qualify for start of treatment, patients need to a) Be within 7 days of symptom onset b) Meet criteria for use c) Be able to receive three days of consecutive IV therapy in clinic (in home, by exception).

Patient Demographics & History	
Full Name:	MRN (if available):
Date of Birth:	Patient HCN (include Version Code):
Address:	
Phone Number:	Email:
Allergies:	OR <input type="checkbox"/> No known allergies
Patient has a history of serious adverse or allergic reaction to the prescribed medication or related compound?	<input type="checkbox"/> Yes <input type="checkbox"/> No
Brief medical history & current medication list (prescription, non-prescription, over the counter and herbal) <i>Where applicable, documentation with this information can be attached</i>	<input type="checkbox"/> Documentation attached <input type="checkbox"/> Patient reviewed for drug-drug interactions
Criteria for Use	
Date of Symptom Onset:	Date of Positive Test:
Test Type: <input type="checkbox"/> PCR Test <input type="checkbox"/> Rapid Antigen Test <input type="checkbox"/> Rapid Molecular Test	
Prescriber acknowledges Ontario Health (OH) & MOH guidelines have been met:	<input type="checkbox"/> Yes <input type="checkbox"/> No
Please select the eligibility criteria the patient meets:	
<input type="checkbox"/> Adults ≥60 years of age with no other risk factors (regardless of vaccination status)	
<input type="checkbox"/> Adults with one or more <u>underlying conditions</u> that puts them at high risk for severe COVID-19 outcomes	
<input type="checkbox"/> Immunocompromised adults ≥18 (regardless of age, vaccination status, or prior infections). Examples: <ul style="list-style-type: none"> active hematological malignancy or post stem cell transplant or CAR T-cell therapy in last 6 months solid organ transplant hypogammaglobulinemia taking prednisone greater than 20 mg/day (or equivalent) for more than 14 days other moderately or severely immunosuppressive therapies (example: anti-CD20 agents, alkylating agents, cancer chemotherapy) 	<input type="checkbox"/> Adults with inadequate immunity, such as: <ul style="list-style-type: none"> Unvaccinated or under-vaccinated (example: completed primary series AND last COVID-19 vaccine dose was more than 6 months ago AND last SARS-CoV-2 infection was more than 6 months ago). See the most recent immunization guidance from National Advisory Committee on Immunization to determine if your patient is under-vaccinated.
Renal Function	Creatinine umol/L: _____ eGFR: _____ <input type="checkbox"/> Not Available Please specify reason for approval: _____ (Note: no dose adjustment required with impaired renal function, including patients on dialysis)

Patient Demographics & History			
Full Name:		Date of Birth:	
Patient HCN (include Version Code):			
Criteria for Use (cont'd)			
Liver Function	ALT:	ALP:	Bili: Date: <input type="checkbox"/> Not Available
	INR:	Date:	<input type="checkbox"/> Not Available
Complex patient requiring consultation by ID:	<input type="checkbox"/> Yes <input type="checkbox"/> N/A	If yes, <input type="checkbox"/> Documentation attached ID Physician Consulted:	
Patient willing to travel to receive treatment (three consecutive days):		<input type="checkbox"/> Yes <input type="checkbox"/> No	
Request for patient to receive follow up care from the COVID Care Clinic post-Remdesivir treatment:		<input type="checkbox"/> Yes <input type="checkbox"/> No	
For patients receiving a First Dose			
Is patient on beta-blockers?		<input type="checkbox"/> Yes <input type="checkbox"/> No	
<i>Please note: as per the latest OH guidelines, there are no contraindications for patients on beta blockers and the benefit of Remdesivir treatment outweighs the risk</i>			
Remdesivir Prescription			
Remdesivir Prescription (no dose adjustments required for eGFR less than 30 per advisement by Infectious Diseases physicians): <input type="checkbox"/> Remdesivir 200mg IV day 1, followed by Remdesivir 100mg, IV on Day 2 and Remdesivir 100mg, IV on Day 3 <input type="checkbox"/> Remdesivir 100mg IV on Day 2 and Remdesivir 100mg IV on Day 3 Day 1 already completed on date and time: <input type="checkbox"/> IV Remdesivir _____			
NOTE: Administer Remdesivir per institution/clinic policy. No refills. Remdesivir must be given over three consecutive days, unless otherwise indicated.			
Dose Adjustments (please note if there are any medications being held or adjusted below): Hold _____ for _____ days from starting Remdesivir			
Note: This prescription to only for Remdesivir and not intended for any other medications. Please fill out a separate prescription if your patient requires additional medications.			
Administration Orders			
<input type="checkbox"/> Insert saline lock and keep for 3 days for Remdesivir treatment, discontinue saline lock after treatment is complete			
Prescriber Attestation			
<input type="checkbox"/> I affirm that the patient meets the above criteria for use and appropriate assessment has been completed.			
Physician/NP Name:		Phone Number:	
Email:		CPSO#:	
Physician/NP Signature:		Date:	